We have now evaluated the efficacy of an anti-CEA nanobody (NbCEA5) site-specifically conjugated to IRDye800 for tumor-specific FGS in an orthotopic mouse model of pancreatic cancer [24]. Here, CEACAM5 is linked to familial pancreatic carcinoma.